v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Grant revenue   $ 1,848   $ 282,422
Operating expenses:        
Research and development $ 3,340,592 1,638,917 $ 7,413,801 6,034,196
General and administrative 1,832,937 1,480,319 5,222,320 4,838,969
Total operating expenses 5,173,529 3,119,236 12,636,121 10,873,165
Loss from operations (5,173,529) (3,117,388) (12,636,121) (10,590,743)
Other income (expense):        
Interest income 360,702 150,669 854,409 533,422
Other income     79,000  
Foreign currency gain (loss) 2,847 (5,691) 13,511 (86,618)
Total other income 363,549 144,978 946,920 446,804
Net loss (4,809,980) (2,972,410) (11,689,201) (10,143,939)
Other comprehensive income (loss):        
Foreign currency translation 8,583 (1,117) 25,680 (2,155)
Total comprehensive loss $ (4,801,397) $ (2,973,527) $ (11,663,521) $ (10,146,094)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.09) $ (0.47) $ (0.29) $ (1.65)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.09) $ (0.47) $ (0.29) $ (1.65)
Weighted-average common shares outstanding, basic (in shares) 53,680,979 6,372,938 40,759,485 6,151,433
Weighted-average common shares outstanding, diluted (in shares) 53,680,979 6,372,938 40,759,485 6,151,433